Erratum: CDK4 is an essential insulin effector in adipocytes (The Journal of Clinical Investigation (2016) 126: 1 (335–348) DOI: 10.1172/JCI81480);CDK4 is an essential insulin effector in adipocytes

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 335-348

  Lagarrigue, Sylviane ^a,b   Lopez Mejia, Isabel C ^a   Denechaud, Pierre Damien ^a   Escoté, Xavier ^a   Castillo Armengol, Judit ^a   Jimenez, Veronica ^c   Chavey, Carine ^b   Giralt, Albert ^a   Lai, Qiuwen ^a   Zhang, Lianjun ^a   Martinez Carreres, Laia ^a   Delacuisine, Brigitte ^a   Annicotte, Jean Sébastien ^b,d   Blanchet, Emilie ^b   Huré, Sébastien ^a,b   Abella, Anna ^e   Tinahones, Francisco J ^f,g   Vendrell, Joan ^h   Dubus, Pierre ⁱ   Bosch, Fatima ^c   Kahn, C Ronald ^j   Fajas, Lluis ^a,b   more..

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIV LILLE   (France)

^e INSERM   (France)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

^j HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; PALBOCICLIB; CCND3 PROTEIN, HUMAN; CDK4 PROTEIN, MOUSE; CYCLIN D3; E2F1 PROTEIN, MOUSE; INSULIN RECEPTOR SUBSTRATE; IRS2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR E2F1;

ADIPOCYTE; ADIPOGENESIS; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; FEMALE; GENE EXPRESSION; HUMAN; LIPOLYSIS; MALE; MOUSE; NONHUMAN; OBESITY; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WHITE ADIPOSE TISSUE; 3T3-L1 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; INSULIN RESISTANCE; LIPID METABOLISM; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOSE TISSUE, WHITE; ANIMALS; CYCLIN D3; CYCLIN-DEPENDENT KINASE 4; E2F1 TRANSCRIPTION FACTOR; FEMALE; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84956676264     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI162359     Document Type: Erratum

References (45)

1. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799-806.
2. White MF. Insulin signaling in health and disease. Science. 2003;302(5651):1710-1711.
3. Rask-Madsen C, Kahn CR. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2012;32(9):2052-2059.
4. Vazquez-Vela ME, Torres N, Tovar AR. White adipose tissue as endocrine organ and its role in obesity. Arch Med Res. 2008;39(8):715-728.
5. Koch L, et al. Central insulin action regulates peripheral glucose and fat metabolism in mice. J Clin Invest. 2008;118(6):2132-2147.
6. Abel ED, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001;409(6821):729-733.
7. Choi YH, et al. Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. J Clin Invest. 2006;116(12):3240-3251.
8. Matsushime H, et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/ cdk4) for mammalian D type G1 cyclins. Cell. 1992;71(2):323-334.
9. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997;8(2):287-301.
10. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 2009;9(3):153-166.
11. Rane SG, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet. 1999;22(1):44-52.
12. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704-707.
13. Martin J, et al. Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene. 2003;22(34):5261-5269.
14. Abella A, et al. Cdk4 promotes adipogenesis through PPARgamma activation. Cell Metab. 2005;2(4):239-249.
15. Sarruf DA, Iankova I, Abella A, Assou S, Miard S, Fajas L. Cyclin D3 promotes adipogenesis through activation of peroxisome proliferatoractivated receptor gamma. Mol Cell Biol. 2005;25(22):9985-9995.
16. Fajas L, Landsberg RL, Huss-Garcia Y, Sardet C, Lees JA, Auwerx J. E2Fs regulate adipocyte differentiation. Dev Cell. 2002;3(1):39-49.
17. Jimenez V, et al. In vivo adeno-associated viral vector-mediated genetic engineering of white and brown adipose tissue in adult mice. Diabetes. 2013;62(12):4012-4022.
18. Sotillo R, et al. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 2001;20(23):6637-6647.
19. Rodriguez-Diez E, et al. Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis. Blood. 2014;124(15):2380-2390.
20. Zechner R, et al. FAT SIGNALS - lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 2012;15(3):279-291.
21. Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427-1438.
22. Hilhorst R, Houkes L, Mommersteeg M, Musch J, van den Berg A, Ruijtenbeek R. Peptide microarrays for profiling of serine/threonine kinase activity of recombinant kinases and lysates of cells and tissue samples. Methods Mol Biol. 2013;977:259-271.
23. Thirone AC, Huang C, Klip A. Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends Endocrinol Metab. 2006;17(2):72-78.
24. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30(11):630-641.
25. Viglietto G, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002;8(10):1136-1144.
26. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/ WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001;3(3):245-252.
27. Reuveni H, et al. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res. 2013;73(14):4383-4394.
28. Baserga R. The insulin receptor substrate-1: A biomarker for cancer? Exp Cell Res. 2009;315(5):727-732.
29. Heilmann AM, et al. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Res. 2014;74(14):3947-3958.
30. Vora SR, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014;26(1):136-149.
31. Muranen T, Meric-Bernstam F, Mills GB. Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors. Cancer Cell. 2014;26(1):7-9.
32. Miller ML, et al. Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. Sci Signal. 2013;6(294):ra85.
33. Turner NC, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209-219.
34. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclindependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130-146.
35. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763-777.
36. Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia. 2012;55(10):2565-2582.
37. Solinas G, Naugler W, Galimi F, Lee MS, Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci U S A. 2006;103(44):16454-16459.
38. Sharfi H, Eldar-Finkelman H. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. Am J Physiol Endocrinol Metab. 2008;294(2):E307-E315.
39. Fritsche L, et al. Insulin-induced serine phosphorylation of IRS-2 via ERK1/2 and mTOR: studies on the function of Ser675 and Ser907. Am J Physiol Endocrinol Metab. 2011;300(5):E824-E836.
40. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab. 2009;296(4):E581-E591.
41. Blanchet E, et al. E2F transcription factor-1 regulates oxidative metabolism. Nat Cell Biol. 2011;13(9):1146-1152.
42. Withers DJ, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 1998;391(6670):900-904.
43. Tsuruzoe K, Emkey R, Kriauciunas KM, Ueki K, Kahn CR. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1-and IRS-2-mediated signaling. Mol Cell Biol. 2001;21(1):26-38.
44. Benhamed F, et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest. 2012;122(6):2176-2194.
45. Annicotte JS, et al. The CDK4-pRB-E2F1 pathway controls insulin secretion. Nat Cell Biol. 2009;11(8):1017-1023.